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RhoA and  PKC Control Distinct Modalities of LFA-1
Activation by Chemokines: Critical Role of LFA-1
Affinity Triggering in Lymphocyte In Vivo Homing
affinity state and of lateral mobility (Constantin et al.,
2000; Laudanna et al., 2002). These modalities of integrin
activation play a cooperative role in mediating LFA-1-
dependent lymphocyte immediate arrest on ICAM-1 un-
der physiologic flow conditions. In particular, induction
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In this study we addressed the possibility that RhoAChemokines regulate rapid leukocyte adhesion by
triggering a complex modality of integrin activation. and  PKC may control different modalities of LFA-1
activation by chemokines. We found that RhoA and We show that the small GTPase RhoA and the atypical
 PKC differently control lymphocyte LFA-1 high-affin- PKC play diversified, yet necessary, roles in rapid LFA-1
triggering by chemokines in lymphocytes. RhoA controlsity state and rapid lateral mobility induced by chemo-
kines. Activation of LFA-1 high-affinity state and lateral both LFA-1 high-affinity state and lateral mobility induc-
tion by chemokines through the engagement of distinctmobility is controlled by RhoA through the activity of
distinct effector regions, demonstrating that RhoA is RhoA downstream effector regions. In contrast,  PKC
is involved only in heterodimer lateral mobility induction.a central point of diversification of signaling pathways
leading to both modalities of LFA-1 triggering. In con- Importantly, we show that blockade of RhoA down-
stream effector region specifically involved in the induc-trast,  PKC controls LFA-1 lateral mobility but not
affinity triggering. Blockade of the 23–40 RhoA effector tion of LFA-1 high-affinity state prevents rapid arrest
of circulating naive lymphocytes on ICAM-1-expressingregion prevents induction of LFA-1 high-affinity state
as well as lymphocyte arrest in Peyer’s patch high high endothelial venules (HEV) in secondary lymphoid
organs. These findings show that RhoA and  PKC areendothelial venules. Thus, RhoA controls the induction
of LFA-1 high-affinity state by chemokines indepen- critical points of diversification in signal transduction
pathways generated by chemokines and leading todently of  PKC, and this is critical to support chemo-
kine-regulated homing of circulating lymphocytes. LFA-1 activation. Moreover, the data illuminate the criti-
cal physiological role of triggering LFA-1 to high-affinity
state in lymphocyte homing in vivo.Introduction
The concerted action of adhesion molecules and che- Results
mokine receptors regulates leukocyte extravasation
from the blood and determines the specificity of the A Novel Method for Analyzing RhoA
immune response (Kunkel and Butcher, 2002). Chemo- Signaling Activity
kines activate an extremely rapid and complex modality Three distinct regions of RhoA have been shown to
of integrin activation consisting of heterodimer high- activate individual downstream effectors (Fujisawa et
al., 1998). To block RhoA-dependent signaling in a re-
gion-selective manner, we generated fusion peptides*Correspondence: carlo.laudanna@univr.it
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Figure 1. P1-RhoA Peptides Are Effective Inhibitors of RhoA-Dependent Signaling
(A) RhoA binding to Citron-, Rhotekin- and ROCK-RBD in the presence of buffer (Control) or 20 g of Penetratin-1 (P1) or 23–40, 75–92, and
92–119 P1-RhoA peptides. A protein immunoblot of anti-RhoA is shown. One representative experiment of two.
(B) Densitometric analysis of the immunoblot shown in (A).
(C) Swiss 3T3 mouse fibroblasts were treated for 4 hr at 37C with 50 M of Penetratin-1 (P1) or different P1-RhoA peptides and then stimulated
for 10 min with 25 ng/ml lysophosphatidic acid (LPA). Shown are confocal microscopy images.
(D) Human polymorphonuclear neutrophils were treated for 2 hr at 37C with 50 M of P1 or different P1-RhoA peptides and then stimulated
with 10 ng/ml PMA or 100 nM formyl-Met-Leu-Phe (fMLP). Stimulation was performed under stirring at 37C. Shown are nmoles of released
H2O2. Values are the means from three experiments. Error bars are SDs.
including an N-terminal plasma membrane translocating in fibroblasts, a phenomenon dependent on RhoA-acti-
vated Rho-kinase (ROCK) (Amano et al., 1997). Pretreat-sequence from the third helix of the homeoregion of
Drosophila melanogaster transcription factor Anten- ment of fibroblasts with each peptide almost completely
prevented the accumulation of stress fibers upon LPAnapedia, also called Penetratin-1 (P1) (Prochiantz, 2000),
fused to the three distinct downstream effector regions triggering. In contrast, the peptide encompassing only
the P1 sequence was completely ineffective (Figure 1C).of human RhoA, encompassing amino acids 23–40, 75–
92, and 92–119. Inhibition was dose dependent with significant effects
starting at 10 M (data not shown). These results areWe first evaluated the ability of the peptides to block
RhoA interaction with specific effectors. In pull-down consistent with the known involvement of these RhoA
sites in ROCK activation and with the result of our pull-assays, binding of RhoA to Citron was blocked by 23–40,
but not 75–92 and 92–119, peptides; binding to Rhotekin down experiment. In contrast, LPA-induced membrane
ruffling, which is Rac1 dependent (Ridley and Hall, 1992),was blocked by 75–92, but not 23–40 and 92–119, pep-
tides; finally, binding to ROCK was inhibited by all the was unaffected by pretreatment with the peptides (data
not shown). Furthermore, in human polymorphonuclearpeptides (Figures 1A and 1B). These data are in agree-
ment with a previous study (Fujisawa et al., 1998) and neutrophils, the peptides were unable to block the phor-
bol myristate acetate (PMA)- and formyl-Met-Leu-Pheshow that soluble RhoA-derived effector regions may
block RhoA interaction with specific effectors. As the (fMLP)-induced activation of the superoxide forming
complex NADPH-oxidase, whose activation relies on racthree peptides were able to significantly prevent RhoA
interaction with ROCK, we could validate the biological activity (Abo et al., 1991) (Figure 1D). Together, these
data show that P1-RhoA fusion effector regions are ef-activity of the peptides by testing the capability of P1-
RhoA peptides to interfere with the accumulation of ac- fective selective inhibitors of RhoA-induced signaling
events.tin stress fibers induced by lysophosphatidic acid (LPA)
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Figure 2. RhoA Control LFA-1 High-Affinity State and Lateral Mobility Triggering by CCL21
(A) ICAM-1 was immobilized at the indicated site densities. Lymphocytes were treated at 37C for 60 min with buffer (n.a. and C) or with the
indicated M doses of P1 or different P1-RhoA peptides and then stimulated for 2 min with buffer (n.a., no agonist) or with 1 M CCL21.
Values are mean counts of adherent cells in six to nine experiments. Error bars are SDs. *p  0.01.
(B) Lymphocytes were stimulated at 37C under stirring with 1 M CCL21 for the indicated time; time 0 corresponds to no agonist. A protein
immunoblot of anti-RhoA in lysates (top) and precipitates (bottom) is shown. One representative experiment of three.
(C) Lymphocytes were treated at 37C for 60 min with 100 M of 125I P1 or P1-RhoA peptides. Values are the mean numbers of internalized
molecules per cell in three experiments. Error bars are SDs.
(D and E) (D) RhoA controls the induction of LFA-1 high-affinity state by CCL21. Lymphocytes were treated at 37C for 60 min with buffer
(n.a. and control), with 100 M of P1 or different P1-RhoA peptides, or (E) with the indicated concentrations of P1-23/40 RhoA region, and
then stimulated for 2 min with buffer (no agonist) or with 1 M CCL21. The mean CPM from 125I-ICAM-1 in three experiments is shown. Error
bars are SDs. *p  0.01.
(F) RhoA controls the induction of LFA-1 rapid lateral mobility on the plasma membrane induced by CCL21. Lymphocytes were treated as
described for (D), and then stimulated at 37C for 2 min with 1 M CCL21. Confocal images of LFA-1 surface distribution are shown. Arrows
indicate LFA-1 clusters.
(G) ICAM-1 was immobilized at the indicated site densities. Lymphocytes were treated at 37C 30 min with buffer (n.a. and control) or with
50 M Y27632 and then stimulated for 2 min with buffer (no agonist) or with 1 M CCL21. Values are the mean counts of adherent cells in
three experiments. Error bars are SDs.
(H) Lymphocytes were treated with 50 M Y27632. LFA-1 affinity triggering was evaluated as described for (D). Values are from three
experiments. Error bars are SDs.
Distinct RhoA Effector Regions Control Chemokine- to block rapid adhesion triggering. However, on high
density of ICAM-1 (5000 sites/m2), only the 23–40 P1-Induced LFA-1-Dependent Rapid Lymphocyte
Adhesion to ICAM-1 RhoA peptide blocked adhesion triggering in a dose-
dependent manner, whereas P1, 75–92, and 92-119 P1-To evaluate the role of RhoA in the complex modality
of LFA-1 activation by chemokines, we first investigated RhoA peptides were ineffective (Figure 2A). None of
the used peptides interfered with intracellular calciumthe involvement of RhoA in CCL21-induced rapid LFA-1-
dependent lymphocyte adhesion to ICAM-1 immobilized increase induced by CCL21, thus ruling out potential
nonspecific effects (data not shown). RhoA involvementat either low or high site densities. When lymphocytes
were stimulated to adhere to low density of ICAM-1 in CCL21-induced LFA-1-dependent lymphocyte adhe-
sion was further corroborated by biochemical analysis(500 sites/m2), both 23–40 and 92–119 P1-RhoA pep-
tides prevented in a dose-dependent manner rapid ad- showing that CCL21 activated RhoA within seconds,
thus displaying kinetics consistent with rapid LFA-1 trig-hesion induced by CCL21 (Figure 2A). In contrast, the
75–92 P1-RhoA peptide or the P1 peptide was unable gering (Figure 2B). To exclude that the difference be-
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Taken together, these data show that RhoA controlsTable 1. Quantitative Analysis of the Effect of RhoA, ROCK, and 
PKC Inhibition on LFA-1 Plasma Membrane Distribution by CCL21 both modalities of chemokine-induced rapid LFA-1 acti-
vation by means of distinct effector regions. Interestingly,LFA-1 Distribution
the 75–92 effector region, involved in ROCK activation,on Plasma Membrane
does not appear to have a role in chemokine-induced
Disperse (%) Clusters (%) integrin activation. Notably, 23–40 and 92–119 RhoA re-
gions have been also implicated in ROCK activationNo agonist 88  14 12  8
(Fujisawa et al., 1998). Therefore, we wished to deter-Control 21  10 79  11
mine whether ROCK could be an effector in RhoA-Penetratin-1 (P1) 30  17 70  13
dependent LFA-1 rapid activation by chemokines. Pre-P1-23/40 60  14 40  16
P1-75/92 14  10 86  11 treatment of lymphocytes with Y27632, a specific ROCK
P1-92/119 79  13 21  8 inhibitor (Uehata et al., 1997), did not inhibit CCL21-
CCL21 Y27632 23  12 77  14 induced lymphocyte adhesion to ICAM-1 immobilized
Myr- PKC 22  5 78  12
either at low or high site density (Figure 2G). Further-Myr- PKC 17  8 83  16
more, neither LFA-1 affinity triggering (Figure 2H) norMyr-	 PKC 25  10 75  11
induction of lateral mobility (Table 1) were blocked byMyr- scramble 19  9 81  19
Myr- PKC 81  18 19  7 Y27632. These data rule out ROCK as a possible down-
stream signaling effector linking RhoA to rapid LFA-1Lymphocytes were treated with buffer (Control), 50 M P1 or differ-
activation by chemokines.ent P1-RhoA peptides, 50 M of Y27632 or with 100 M of PKC
myristoylated pseudosubstrate peptides, and then stimulated for 2
min with buffer (no agonist) or with 1M CCL21. At least 100 cells for The Atypical  PKC Is Involved in Chemokine-Induced
each data point were analyzed. Values are mean SD percentage of LFA-1-Dependent Rapid Lymphocyte
analyzed cells in three experiments.
Adhesion to ICAM-1
Previous data proposed  PKC as potential RhoA ef-
fector implicated in Mac1 activation by chemoattrac-tween P1-RhoA peptides in lymphocytes could be due
tants in polymorphonucelar cells (PMNs) (Laudanna etto unequal accumulation of the peptides into the cell, we
al., 1998). To evaluate the role of  PKC in rapid LFA-1calculated the number of molecules of different peptides
triggering by chemokines in lymphocytes, we used myri-loaded per single cell. Although the P1 peptide loaded
stoylated peptides with sequence identical to the pseu-more efficiently, all three different P1-RhoA peptides
dosubstrate inhibitory region of  PKC (Laudanna et al.,showed a similar capability to accumulate inside lym-
phocytes (Figure 2C). 1998). As shown in Figure 3A, blockade of  PKC activity
Together, these data show that RhoA controls LFA-1 inhibited in a dose-dependent manner adhesion trig-
activation by CCL21 through the signaling activity of gering to ICAM-1 induced by CCL21. Notably, the inhibi-
two distinct effector regions. tory effect of the  PKC peptide was evident only on
low density of ICAM-1. Moreover, a control peptide, with
Distinct RhoA Effector Regions Control the Different a scrambled sequence (Figure 3A), as well as peptides
Modalities of LFA-1 Activation by Chemokines with sequence identical to the pseudosubstrate region
Chemokine-triggered lymphocyte arrest in condition of of , , and 	 PKCs (Figure 3B) were completely unable
variable density of ICAM-1 relies on distinct intracellular to prevent adhesion triggering either on low or high
signaling pathways specifically controlling the two mo- density of ICAM-1. To further corroborate the involve-
dalities of LFA-1 activation (Constantin et al., 2000). ment of  PKC in signaling pathways generated by che-
Thus, the previous data strongly suggest that RhoA acti- mokines and leading to LFA-1 activation, we analyzed
vates both modalities of LFA-1-activation through the the activation state of  PKC upon CCL21 stimulation.
distinct signaling activity of 23–40 and 92–119 effector As shown in Figure 3C, CCL21 induced a consistent
regions. To test this hypothesis, we evaluated the capa- and rapid increase of  PKC kinase activity. We also
bility of different P1-RhoA peptides to interfere with evaluated the intracellular distribution of  PKC. As
LFA-1 high-affinity state and rapid lateral mobility trig- shown in Figure 3D, in resting lymphocytes  PKC was
gering by chemokines. Pretreatment with the P1 control mainly associated with the particulate fraction, whereas
or the 75–92 and 92–119 P1-RhoA peptides did not pre-
it was almost absent in the cytosol and plasma mem-
vent LFA-1 high-affinity state triggering (Figure 2D). In
brane. Upon triggering with CCL21,  PKC rapidly trans-contrast, pretreatment of lymphocytes with the 23–40
located to the plasma membrane fraction. These dataP1-RhoA peptide prevented heterodimer high-affinity
show that the atypical  PKC is the only PKC isoformstate induction by CCL21 (Figure 2D). Inhibition of LFA-1
expressed in lymphocytes selectively involved in rapidhigh-affinity state triggering by the 23–40 P1-RhoA pep-
LFA-1 triggering by chemokines. Importantly,  PKCtide was dose dependent and almost complete, with a
seems relevant only to adhesion to low density ofmaximum blockade of about 90% (Figure 2E).
ICAM-1.We next determined the involvement of RhoA in the
induction of rapid LFA-1 lateral mobility by CCL21. Pre-
The Atypical  PKC Controls LFA-1 Lateral Mobilitytreatment with the P1 control peptide or with the 75–92
but Not High-Affinity State InductionP1-RhoA peptide did not prevent LFA-1 rapid lateral
by Chemokinesmobility induced by CCL21. In contrast, pretreatment
The previous data suggest a role for  PKC in LFA-1with both 23–40 and 92–119 P1-RhoA peptides pre-
lateral mobility but not high-affinity state induction byvented rapid generation of LFA-1 clusters (Figure 2F
and Table 1). CCL21. To validate this hypothesis we determined the
RhoA and  PKC in Integrin Activation by Chemokines
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Figure 3.  PKC Is Involved in LFA-1 Activation by CCL21
(A) ICAM-1 was immobilized at the indicated site densities. Lymphocytes were treated at 37C for 60 min with buffer (n.a. and control) or with
50 M of a scramble peptide (scr) or with the indicated doses of  PKC myristoylated pseudosubstrate peptides and then stimulated for 3
min with buffer (n.a., no agonist) or with 1 M CCL21. Values are the mean counts of adherent cells in five experiments. Error bars are SDs.
(B) ICAM-1 was immobilized at the indicated site densities. Lymphocytes were treated at 37C for 60 min with buffer (n.a. and control) or with
the indicated dose of various PKC myristoylated pseudosubstrate peptides and then stimulated for 3 min with buffer (no agonist) or with
1 M CCL21. Values are the mean counts of adherent cells in four experiments. Error bars are SDs.
(C) Lymphocytes were treated at 37C for 30 min with buffer (no agonist and control) or with 150 nM Wortmannin or 30 M LY294002 and
then stimulated at 37C under stirring for 30 or 60 s with buffer (no agonist) or with 1 M CCL21. No agonist w/o MBP is radioactive in the
absence of exogenous substrate and is a measurement of  PKC autophosphorylating activity in nonstimulated lymphocytes. Values are the
mean counts of two experiments performed in duplicate. Error bars are SDs.
(D) Lymphocytes were treated at 37C for 30 min with buffer (no agonist and control), with 100 M of P1 or P1-RhoA peptides, or with 150
nM Wortmannin and then stimulated at 37C under stirring for 30 s with buffer (no agonist) or with 1 M CCL21. Shown are protein immunoblots
of cytosolic (C), light membrane (M), and particulate (P) fractions separated on sucrose gradient and probed with anti- PKC Ab.
role of  PKC in LFA-1 high-affinity state and lateral CCL21. In contrast, the atypical isoform  PKC is neces-
sary for LFA-1 lateral mobility on the plasma membranemobility induction by CCL21. As shown in Figure 4A,
pretreatment of lymphocytes with  PKC inhibitory pep- induced by CCL21.
tides or with a scrambled peptide did not prevent the
rapid and transient induction of LFA-1 high-affinity state
induced by CCL21. , , and 	 PKC inhibitory peptides The Role of PI(3)K and RhoA in  PKC
Activation by Chemokineswere also unable to block LFA-1 high-affinity state in-
duction (data not shown). However, confocal micros- PI(3)K has been previously implicated in LFA-1 lateral
mobility (Constantin et al., 2000) as well as in  PKCcopy analysis showed that pretreatment of lymphocytes
with the  PKC inhibitory peptide, but not with a scram- activation (Le Good et al., 1998). As shown in Figure 3C,
pretreatment of lymphocytes with Wortmannin or withbled peptide, prevents the accumulation of large LFA-1
clusters rapidly induced by CCL21 (Figure 4B and Table LY234002, two PI(3)K specific inhibitors, partially pre-
vented the increase of  PKC kinase activity induced by1). , , and 	 PKC blocking peptides were completely
unable to inhibit LFA-1 cluster formation induced by CCL21 (about 51% for Wortmannin and 62% for
LY294002). In contrast, pretreatment with PI(3)K inhibi-CCL21 (Table 1).
Together, these data show that classical, novel, and tor did not affect  PKC translocation to the plasma
membrane (Figure 3D). Thus, PI(3)K partially mediatesatypical PKCs isoforms expressed in lymphocytes are
not involved in LFA-1 high-affinity state triggering by CCL21-induced increase of kinase activity but not trans-
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dependent signaling activated by the 23–40 down-
stream effector region.
RhoA-Dependent LFA-1 High-Affinity State Is the
Modality of Integrin Activation Controlling
Lymphocyte Homing In Vivo
The data presented above establish diversified roles for
RhoA and  PKC in controlling distinct modalities of
LFA-1 activation. Previous data suggested a role for
LFA-1 triggered to high-affinity state in lymphocyte hom-
ing to secondary lymphoid organs. However, a formal
demonstration has never been provided. The definition
of the role of 23–40 RhoA region in LFA-1 high-affinity
state triggering by chemokines prompted us to pursue
a formal demonstration of the role of LFA-1 triggering
to high-affinity state in the recruitment of circulating
lymphocytes in vivo.
Pretreatment of lymphocytes with the P1 control pep-
tide or with the 75–92 or 92–119 P1-RhoA peptides did
not affect rolling and arrest of circulating lymphocytes
on high endothelial venules in the secondary lymphoid
organ Peyer’s patch (PP-HEV) (Figure 5). Pretreatment
with the 23–40 P1-RhoA peptide did not influence lym-
phocyte tethering and allowed normal interaction with
vessels (data not shown). However, this peptide consis-
tently inhibited the stable arrest of lymphocytes on PP-
HEV, with about 75% of inhibition (p0.01); the percent-
age of cells displaying only rolling increased, as ex-
pected. Notably, the site density of ICAM-1 presented to
the interacting lymphocytes on PP-HEV was previously
shown to be extremely high (about 14,000 site/m2)
(Constantin et al., 2000), a condition in which LFA-1
accelerated lateral mobility is not required to rapid ar-Figure 4.  PKC Control LFA-1 Lateral Mobility but Not High-Affinity
rest. Indeed, the 92–119 P1-RhoA peptide, which onlyState Triggering by CCL21
affected LFA-1 rapid lateral mobility induced by CCL21,(A) Lymphocytes were treated at 37C for 60 min with buffer (no
agonist and control), or with 50 M scramble peptide (scr) or  PKC had no effect on lymphocyte arrest in PP-HEV. As the
myristoylated pseudosubstrate peptide and then stimulated for 2 23–40 RhoA effector region controls the induction of
min with buffer (no agonist) or with 1 M CCL21. The mean CPM LFA-1 conformational change by CCL21 (see Figure 2),
from 125I-ICAM-1 is shown. Values are counts from a representative
these data demonstrate that RhoA-controlled hetero-experiment of three.
dimer high-affinity state is the modality of LFA-1 activa-(B) Lymphocytes were treated as in (A) and then stimulated at 37C
tion critically required for rapid arrest of circulating lym-for 2 min with 1 M CCL21. Confocal images of LFA-1 surface
distribution are shown. Arrows indicate LFA-1 clusters. phocytes in PP-HEV.
We also wished to test the role of ROCK kinase and
 PKC in rapid lymphocytes recruitment to HEV. Lym-
phocytes pretreated with Y27632 rolled and adheredlocation of  PKC to the plasma membrane in lympho-
normally in HEV. Moreover, pretreatment of lympho-cytes.
cytes with the  PKC inhibitory peptide did not affectChemoattractant-induced  PKC translocation to the
the capability of lymphocytes to roll and arrest on HEVplasma membrane relies on RhoA activity in PMNs (Lau-
(Figure 5). These data are consistent with the inabilitydanna et al., 1998). Having identified RhoA downstream
of these inhibitors to prevent LFA-1 affinity triggeringeffector regions critical to rapid LFA-1 triggering, we had
by CCL21 and exclude a participation of ROCK and the possibility to investigate the involvement of distinct
PKC in signaling events leading to lymphocyte rapidRhoA effector regions in  PKC translocation induced
arrest in PP-HEV.by chemokines in lymphocytes. As shown in Figure 3D,
pretreatment of lymphocytes with P1 peptide or with
75–92 or 92–119 P1-RhoA peptides did not prevent  Discussion
PKC translocation to the plasma membrane. However,
pretreatment with the 23–40 P1-RhoA peptide blocked Chemokines are the most powerful physiological activa-
tors of lymphocyte integrins (Laudanna et al., 2002). WePKC translocation to the plasma membrane; the densi-
tometric analysis showed a blockade of about 82%. have previously shown that chemokines play a dual role
in LFA-1-mediated rapid lymphocyte adhesion by induc-These data show that induction of  PKC kinase activ-
ity by CCL21 in lymphocytes partially depends on PI(3)K, ing LFA-1 high-affinity state and lateral mobility (Con-
stantin et al., 2000). Here we have identified intracellularwhereas  PKC tranlocation to the plasma membrane
is mainly controlled by a restricted subset of RhoA- signaling events differently controlling this complex
RhoA and  PKC in Integrin Activation by Chemokines
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Figure 5. LFA-1 High-Affinity State Mediates
Lymphocyte Homing to HEV in Peyer’s
Patches
Intravital microscopy was performed in Pey-
er’s patch high endothelial venules. Lympho-
cytes were treated with buffer (control) or with
50 M P1 and P1-RhoA peptides, with 50 M
Y27632, or with 100 M of  PKC myristoy-
lated pseudosubstrate peptide. Values are
the mean percentage of total interacting cells
in three experiments. Error bars are SDs.
*p  0.01.
phenomenon. We presented data regarding the CCR7 never been clarified. The blocking activity of the P1-23-
40 peptide on LFA-1 affinity triggering by CCL21 high-ligand CCL21 which directs T lymphocyte arrest in sec-
ondary lymphoid organs (Warnock et al., 2000). How- lighted the critical regulatory role of RhoA in LFA-1 high-
affinity triggering. Importantly, blockade of 23–40 RhoAever, identical results have been obtained with CCL19
and with the CXCR4 ligand CXCL12 (data not shown), effector region prevented LFA-1-dependent arrest of
naive lymphocytes on PP-HEV. Although 23–40 RhoAthus supporting the general significance of our findings.
We show that: (1) RhoA controls LFA-1 high-affinity region also controls LFA-1 lateral mobility, blockade of
the 92–119 region, which is only involved in heterodimerstate triggering by chemokines; (2) RhoA also controls
LFA-1 lateral mobility induced by chemokines; (3) the lateral mobility, did not interfere with arrest of naive
lymphocytes on PP-HEV. This shows that lymphocytessignaling activity of two distinct RhoA effector regions
controls LFA-1 activation by chemokines; (4) the atypical rely on activation of LFA-1 high-affinity state to home to
secondary lymphoid organs. This provides the definitive PKC is critical to LFA-1 lateral mobility but not to high-
affinity state triggering; (5) chemokine-induced  PKC demonstration of the physiological role of the inside-
out signal-dependent induction of LFA-1 high-affinitykinase activity and translocation to the plasma mem-
brane depend, respectively, on PI(3)K and on the signal- state in vivo.
Biochemical analysis showed a rapid and prolongeding activity of the 23–40 RhoA effector region; and (6)
rapid arrest of circulating lymphocytes on HEV in sec- RhoA activation by CCL21, with RhoA remaining in an
active state for at least 10 min. Notably, the inductionondary lymphoid organs critically depends on the induc-
tion of LFA-1 high-affinity state. of LFA-1 high-affinity state by chemokines displays tran-
sient kinetics, with integrin affinity completely down-
modulated within a few minutes (Constantin et al., 2000).RhoA and the Modality of LFA-1 Activation
by Chemokines This suggests that downmodulation of LFA-1 high-affin-
ity state, which temporally correlates with downmodula-We showed that plasma membrane translocating RhoA-
derived effector regions are useful tools for studying tion of lymphocyte rapid adhesion to ICAM-1, does not
simply rely on RhoA inactivation. Thus, it is possibleRhoA-dependent signaling events in a region-selective
manner. The inhibitory, more than agonistic, activity of that chemokines generate signaling pathways able to
actively counterbalance RhoA-dependent pathwaysthe regions is likely due to interference with the plasma
membrane docking function of small GTPases, a step leading to LFA-1 conformational changes. Notably, the
activation of H-ras and the dependent MAP-kinase pre-required to full activation of downstream effectors
(Stokoe et al., 1994). By using these tools, we analyzed vents the induction of LFA-1 high-affinity state by the
chemokine CXCL12 (Weber et al., 2001b). Thus, it isthe role of RhoA in LFA-1-dependent rapid lymphocyte
adhesion. Our data show that RhoA controls LFA-1 con- possible that a temporally and spatially regulated bal-
ance between the signaling activities of H-ras and RhoAformational change and lateral mobility by chemokines
through the distinct, yet complementary, activity of two could regulate the dynamics of LFA-1 high-affinity state
activation and dependent rapid adhesion.effector regions, encompassing amino acids 23–40 and
92–119. The 92–119 region is exclusively involved in
LFA-1 lateral mobility induction. In contrast, the 23–40  PKC and the Modality of LFA-1
Activation by ChemokinesRhoA region participates in heterodimer lateral mobility
regulation and is also critical to the induction of LFA-1 To deepen the investigation, we determined the involve-
ment of the atypical PKC in LFA-1 activation by chemo-high-affinity state. This latter finding is of particular im-
portance. Indeed, the intracellular signaling events con- kines.  PKC was found to be critical for LFA-1 lateral
mobility but not high-affinity state triggering by CCL21.trolling LFA-1 high-affinity state triggering by chemo-
kines and the physiological meaning of this event have Notably, we have previously shown that LFA-1 lateral
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Figure 6. The Distinct Roles of RhoA and 
PKC in the Different Modalities of Rapid
LFA-1 Activation by Chemokines
(A) Site organization of RhoA and  PKC
showing the effector regions of RhoA (aa
23–40 [A], 75–92 and 92–119 [B]), and the in-
hibitory pseudosubstrate region of  PKC
(aa 113–129).
(B) The plasma membrane translocating pep-
tides displaying inhibitory capability on LFA-1
activation. The 23–40 (1) and 92–119 (2) RhoA
effector regions were fused to Penetratin-1.
A myristic acid was added N-terminal of the
pseudosubstrate region of  PKC (3).
(C) Induction of LFA-1 high-affinity state by
chemokines is controlled by the signaling ac-
tivity of 23–40 downstream effector region of
RhoA (marked with A). Induction of LFA-1 lat-
eral mobility is controlled by  PKC and by
further signals generated by the 92–119
downstream effector region of RhoA (marked
with B). The capability of  PKC to control
LFA-1 lateral mobility depends on transloca-
tion to the plasma membrane, which is con-
trolled by the RhoA 23–40 downstream ef-
fector region, as well as by  PKC kinase
activity.  PKC appears to be an effector of
both PI(3)K and RhoA mediating LFA-1 lateral
mobility induced by chemokines. (1) Inhibi-
tion by the P1-RhoA 23–40 peptide. (2) Inhibi-
tion by the P1-RhoA 92–119 peptide. (3) Inhi-
bition by the myristoylated peptide with
sequence identical to  PKC pseudosub-
strate region.
mobility is not involved in lymphocyte in vivo homing at least partially, the RhoA capability to control LFA-1
clustering. Moreover, this data suggests a direct interac-(Constantin et al., 2000). Therefore, it is not surprising
that  PKC has no role in in vivo lymphocyte homing to tion between RhoA and  PKC, thus establishing  PKC
as a potential direct downstream effector of RhoA. ThisPP. However, as we previously suggested for PI(3)K, 
PKC could have a role in lymphocyte recruitment to possibility is also supported by a previous report (Slater
et al., 2001). However, it is also possible that  PKCvessels expressing low density of integrin ligand, a situa-
tion in which heterodimer lateral mobility is required for translocation is mediated by other RhoA-dependent sig-
naling events. For instance, PLD is activated by directlymphocyte arrest under flow.
Of interest, we also found that the slow LFA-1 cluster- binding with the RhoA switch I region (encompassed by
the 23–40 sequence) (Dae Bae et al., 1998), and PLD-ing induced by PMA is sensitive to  PKC blockade (data
not shown). Accordingly, we previously showed that derived phosphatidic acid (PA) is a powerful  PKC acti-
vator (Limatola et al., 1997). Thus, it is possible that thePMA, although not an allosteric activator of PKC (atypi-
cal PKCs have incomplete C1 region), may trigger  PKC inhibitory effect of the 23–40 P1-RhoA peptide on  PKC
translocation is due to PLD inhibition. Further studiestranslocation to the plasma membrane through RhoA
activation (Laudanna et al., 1998). Notably,  PKC has are required to test these possibilities.
a constitutive kinase activity, and this implies that  PKC
translocation to the plasma membrane may be sufficient The Complexity of the Chemokine-Induced
Proadhesive Signaling Networkto generate  PKC-dependent signaling events even in
the absence of augmented kinase activity. The data presented here, together with previous reports,
further highlight the bewildering complexity of the sig-The ability of the 23–40 P1-RhoA peptide to block 
PKC translocation suggests that  PKC may mediate, naling network generated by chemokines and leading
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to integrin activation. Chemokine-triggered LFA-1 lateral which is not involved in  PKC translocation, suggesting
mobility is controlled at least by PI(3)K, Cytohesin-1, that further RhoA-activated signals are necessary to
Rap1,  PKC, and RhoA. This brings into question the allow LFA-1 mobility on the plasma membrane. Further-
network relationship that these signaling molecules more, recent reports show that additional signals may
have. Recruitment of Cytohesin-1 to the plasma mem- derive from the activity of the small GTPase Rap1 (Shi-
brane requires PI(3)K activity (Nagel et al., 1998). More- monaka et al., 2003). Thus, chemokines trigger at least
over, PI(3)K-derived PIP3 increases  PKC activity, and three independent, yet necessary, signaling pathways
the PIP3-dependent kinase PDK-1 is a direct activator controlled by PI(3)K, Rap1, and RhoA, whose integration
of  PKC (Le Good et al., 1998). Thus, PI(3)K appears to generates a signaling network controlling LFA-1 acceler-
control both Cytohesin-1 and  PKC signaling activity ated lateral mobility on the plasma membrane.
leading to LFA-1 lateral mobility and clustering. How- In conclusion, we show that RhoA and  PKC are
ever, regulation of PKC does not seem to be dependent critical components of the signaling network controlling
on only PI(3)K. Indeed, inhibition of PI(3)K does not to- the complex dynamic of activation of the 2 integrin
tally prevent the increase of  PKC kinase activity in- LFA-1. The small GTP binding protein RhoA is a central
duced by CCL21 and does not block translocation of point of diversification of signaling pathways controlling
 PKC to the plasma membrane. In contrast,  PKC both the modalities of LFA-1 activation induced by che-
translocation to the plasma membrane is critically de- mokines. In contrast,  PKC is a point of convergence
pendent on signaling activity of RhoA 23–40 effector of signaling events controlling only LFA-1 lateral mobility
region. Altogether, these data show that  PKC translo- (Figure 6). Importantly, we formally demonstrate the crit-
cation to the plasma membrane and increase of kinase ical role of LFA-1 affinity triggering in lymphocyte in vivo
activity are independently controlled by distinct signal- homing to PP. Our data suggest that a generic, region-
ing pathways. nonspecific, pharmacological inhibition of RhoA would
Are both of these regulatory mechanisms of  PKC not be the most rational approach for a potential phar-
equally relevant to the activation of LFA-1 lateral mobility macological intervention in RhoA-dependent phenom-
on the plasma membrane? Inhibition of PI(3)K blocks ena. Indeed, a global inhibition of RhoA-dependent sig-
chemokine-induced, but not PMA-triggered, LFA-1 clus- naling activity may prevent LFA-1 high-affinity state
tering (Constantin et al., 2000). In contrast, blockade of triggering and, thus, block lymphocyte recirculation in
 PKC by inhibitory peptides prevents LFA-1 clustering secondary lymphoid organs, an event that is likely to
induced by chemokines as well as by PMA. Thus,  PKC result in undesired side effects. In contrast, selective
translocation to the plasma membrane (which is RhoA blockade of the 92–119 RhoA region could exclusively
dependent in PMA as well as chemokine-triggered sig- inhibit LFA-1 lateral mobility without affecting lympho-
naling) is a very critical biochemical event in LFA-1 clus- cyte homing to secondary lymphoid organs. This mod-
tering. What is the role of the increased  PKC kinase ality of LFA-1 activation was previously postulated to
activity triggered by chemokines? It is important to em- be relevant in the case of variable density of ICAM-1
phasize that chemokines trigger within seconds forma- expressed by the microvasculature, such as during in-
tion of big LFA-1 clusters in lymphocytes, whereas PMA flammation (Constantin et al., 2000). Thus, the identifica-
induces smaller LFA-1 clusters over several minutes tion of discrete RhoA effector regions controlling distinct
(Constantin et al., 2000). In this context, we previously modalities of LFA-1 activation may help to devise a more
hypothesized that PI(3)K, which is not activated by PMA, effective pharmacological approach to control leuko-
could be responsible for acceleration in LFA-1 lateral cyte recruitment during inflammation.
mobility induced by chemokines (Constantin et al.,
2000). The critical role of  PKC in LFA-1 clustering and Experimental Procedures
the capability of PI(3)K to partially mediate the increase
Materialsof PKC activity induced by CCL21 allow a further refine-
PKC myristoylated pseudosubstrate peptides (synthesized at Stan-ment of our previous hypothesis. Thus, it is possible
ford University PAN-facility) were dissolved before use at 1 mMthat RhoA-mediated  PKC translocation triggered by
concentration in PBS (pH 7.2). PMA, ketamine, and xylosine werePMA in the absence of any PI(3)K activation (and thus from Sigma; FCS was from Irvine; murine CCL21 and CXCL12 were
without increase of  PKC activity) may be sufficient form Peprotech (London, United Kingdom); CMFDA, CMTMR, and
to induce a slow LFA-1 lateral mobility on the plasma Alexa 488 labeling kit were from Molecular Probes; Texas red-conju-
membrane. In contrast, the very rapid LFA-1 mobility gated goat anti-rat antibody was from Jackson ImmunoResearch;
murine ICAM-1 was purified from spleens (Constantin et al., 2000).induced by chemokines may require both RhoA-medi-
ated  PKC translocation and a concurrent PI(3)K-
Generation of Penetratin-1-RhoA Peptidesdependent increase of  PKC kinase activity. We then
The Penetratin-1 (P1) fusion protein expression vector pTm3Hb was
hypothesize that a consistent increase of the kinase kindly donated by A. Prochiantz (CNRS, France). Oligonucleotides
activity of  PKC is critical to the acceleration of LFA-1 encompassing human RhoA bases 67–120 (aa 23–40), 223–276 (aa
lateral mobility on the plasma membrane observed upon 75–92), and 274–357 (aa 92–119) were inserted between the BamHI
chemokine stimulation and required for rapid lympho- and KpnI cloning sites. Recombinant proteins expressed in E. coli
BL21(DE3)pLysS Gold were purified on heparin columns, dialyzedcyte arrest in conditions of low density of integrin ligand.
against PBS, and stored at 
80C. Alternatively, P1, P1-23-40, andIt will be of great interest to test this hypothesis under
P1-75-92 peptides were synthesized by Sigma-Genosys. A glycineexperimental conditions allowing a more accurate evalu-
was inserted between P1 and RhoA regions to allow flexibility of
ation of the kinetics of LFA-1 lateral mobility at the single the peptides. Peptides displayed the following properties: P1, aa
molecule level. 16, mw 2246.78; P1-RhoA 23-40, aa 34, mw 4430.29; P1-RhoA 75-92,
Importantly, RhoA controls LFA-1 lateral mobility also aa 34, mw 4254.06; P1-RhoA 92–119, aa 44, mw 5529.83. Lyophilized
peptides were dissolved before the experiments.through the engagement of the 92–119 effector region,
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Specificity of RhoA Peptides and Measurement between 10 and 150 M. Peptide loading was detected after 30
min and reached a plateau within 4–8 hr, depending upon peptideof RhoA Activation
The specificity of P1-RhoA peptides was evaluated by affinity-pre- concentration. The presence of 10% serum did not affect protein
loading.cipitation assay using the rho binding region (RBD) from Citron,
Rhotekin, and ROCK, as described (Ren et al., 1999; Kimura et al.,
2000). Recombinant Val14-RhoA (donated by Dr. A. Hall) was loaded Measurement of LFA-1 High-Affinity State
with 1 mM GTP at 37C for 90 min. Ten micrograms of Citron, Induction of LFA-1 high-affinity state by CCL21 was evaluated by
Rhotekin, or ROCK GST-RBD conjugated with glutathione beads measuring binding of soluble 125I-ICAM-1, as we previously de-
was mixed with 5 g of GTP-Val14-RhoA in 50 l of 50 mM Tris- scribed (Constantin et al., 2000). In brief, ICAM-1 was iodinated with
HCl (pH 7.4), 5 mM MgCl2, 0.5 mM GTP, 2 mg/ml BSA (binding 125NaI by the Chizzonite method. The binding assay was performed
buffer). Binding was for 60 min at 10C. The beads were washed at 37C in a 500 l Eppendorf tube. Forty microliters of lymphocyte
twice with binding buffer and subjected to SDS-polyacrylamide gel suspension (5  107/ml in PBS containing 1 mg/ml BSA, 2 mM
electrophoresis on a 12% gel. RhoA background binding to glutathi- MgCl2, 1 mM CaCl2, 1 mM D-glucose [pH 7.2]) was directly layered
one beads was negligible. In the case of experiments in the presence on 100 l oil cushion of 2/1 dibutyl/dioctyl phthalates. Lymphocytes
of P1-RhoA peptides, the regions were previously dissolved in bind- were stimulated with 10 l of PBS containing chemokine (6 M) and
ing buffer at 1 mg/ml. 125I-ICAM-1 (5  105 CPM corresponding approximately to 2 g of
RhoA activation by CCL21 was evaluated by using the rho binding 125I-ICAM-1). The binding reaction was stopped by rapid centrifuga-
region (RBD) from Rhotekin. Lymphocytes were lysed on ice in 0.5 tion in microfuge. Radioactivity bound to lymphocytes was counted
ml of 100 mM HEPES buffer (pH 7.5), 1% Triton X-100, 1% deoxycho- with a  counter.
late, 0.1% SDS, 500 mM NaCl, 10 mM MgCl2, 2 mM EGTA, 2 mg/ml
BSA, 20 mM benzamidine, containing the Complete Protease Inhibi-
Evaluation of LFA-1 Distribution on Plasma Membranetor Cocktail from Roche. Equal amounts of lysates were incubated
Analysis and quantification of chemokine-induced LFA-1 surfacewith GST-RBD (20 g) beads for 45 min at 4C. Bound GTP-RhoA
distribution was determined by confocal microscopy, following thewas identified by Western blotting using a monoclonal antibody
same procedure previously described (Constantin et al., 2000). Infrom Santa Cruz.
brief, lymphocytes were stimulated in suspension under stirring and
then immediately fixed in 1% ice-cold paraformaldehyde in PBS (pHEvaluation of Actin Stress Fibers Content
7.4) for 10 min. Cell were washed and incubated with 10 g/ml ofSwiss 3T3 mouse fibroblasts were maintained in DMEM containing
TIB213 rat anti-mouse LFA-1 (ATCC) for 30 min on ice, washed three10% FCS for 6 days and then starved for 12 hr. Actin stress fibers
times and then incubated 30 min with Texas red-conjugated goatcontent was evaluated in permeabilized cells with TRITC-labeled
anti-rat secondary antibody. The washed cells adhered for 30 minphalloidin as described (Ridley et al., 1992). Analysis was performed
at 4C on 0.1% poly-L-lysine coated round 13 mm glass coverslipsby using a Zeiss LSM confocal microscope.
and were analyzed with a Carl Zeiss LSM 510 confocal imaging
system, with a 63 C-Apochromat objective (NA 1.2). Definition and
NADPH-Oxidase Activation
quantitative analysis of “disperse” and “clustered” morphologies
Activation of neutrophil NADPH-oxidase was evaluated by measur-
of LFA-1 distribution was as previously described (Constantin et
ing reduction of dihydrorhodamine induced by superoxide anion-
al., 2000).
derived hydrogen peroxide, as previously reported (Laudanna et al.,
1998). Human neutrophils were stimulated under stirring at 37C.
Measurement of  PKC Kinase ActivityTime course of hydrogen peroxide-induced dihydroRhodamine re-
The assay was performed as previously described (Laudanna etduction was evaluated using the spectrofluorimeter with 505 of exci-
al., 1998). In brief, lymphocytes were stimulated under stirring withtation wavelength and 534 of emission wavelength.
agonists at 37C. Stimulation was stopped with lysis buffer con-
taining 50 mM Tris-HCl (pH 7.5), 1% Triton X-100, 0.01% SDS, 150In Vitro Rapid Adhesion Assay on ICAM-1
mM NaCl, 50 mM NaF, 10 mM sodium pyrophosphate, 1 M phen-ICAM-1 was purified from mouse spleens and adhesion assays were
ylarsine oxide, containing the Complete Protease Inhibitor Cocktailperformed as previously reported (Constantin et al., 2000). In brief,
from Roche. After 30 min on ice, lysates were centrifuged at 16,000 gprimary naive lymphocytes (about 70% T, 30% B cells) were isolated
for 1 min to remove cell debris. Rabbit polyclonal anti- PKC (1 g)from peripheral lymph nodes and Peyer’s patches from young
or control rabbit serum was added to an equal amount of cell lysates,BALB/c mice (Harlan, Italy). Cells were resuspended at 4  106/ml
followed by immunoprecipitation with trisacryl protein A. Equalin PBS, CaCl2, MgCl2 1 mM, 10% FCS (pH 7.2). Adhesion assays
amounts of  PKC were immunoprecipitated as confirmed by West-were performed on 18-well glass slides coated overnight at 4C
ern blot analysis (data not shown). After four washings, immunopre-with purified mouse ICAM-1; site density per square micrometer
cipitates were subjected to the kinase reaction for 30 min at 30Cof immobilized ICAM-1 was calculated as reported (Lawrence and
in 50 l of kinase buffer containing 0.5 mM EGTA, 10 mM MgC2, 20Springer, 1991). Twenty microliters of cell suspension was added
mM HEPES (pH 7.4), 50 M ATP, 5 Ci [-32P]ATP, and 2 g myelinto the wells and stimulated at 37C with 5 l of agonists prior to
basic protein (MBP) as a substrate. The reaction was stopped bywashing, fixation, and computer-assisted enumeration of bound
addition of 5% TCA, and the reaction mixture was filtered throughcells.
phosphocellulose paper. After four rinses with 1% phosphoric acid
radioactivity on the filter was determined with a scintillation counter.Calculation of Internalization Efficiency
of the Penetratin-1-RhoA Peptides
Preliminary experiments carried out with fluorescent peptides Evaluation of  PKC Evaluation of Intracellular Distribution
The assay was performed as previously described (Laudanna etshowed that P1 and P1-RhoA peptides accumulated in a compara-
ble manner in about 95% of lymphocytes (data not shown), as also al., 1998). In brief, lymphocytes were stimulated under stirring with
agonists at 37C. Stimulation was stopped by diluting the cells in apreviously reported (Fenton et al., 1998). P1 and P1-RhoA peptides
were labeled with 125I using the Bolton-Hunter reagent (Pierce) fol- 10 larger volume of ice-cold PBS. Cells, resuspended in 1 ml
of ice-cold PBS containing 8% sucrose, containing the Completelowing instructions from the manufacturer. After loading, cells were
rapidly washed three times in PBS, mildly treated with trypsin to Protease Inhibitor Cocktail from Roche, were sonicated, and the
homogenates were centrifuged at 800  g/10 min to remove nucleiremove peptides eventually adsorbed to the outer plasma mem-
brane (Richard et al., 2002), and the internalized radioactivity was and unbroken cells. The postnuclear supernatant was loaded on
discontinuous sucrose gradient (50% sucrose, 30% sucrose) andmeasured with a  counter. Treatment with trypsin removed no more
than 5%–10% of total radioactivity. Specific activity was converted centrifuged for 120 min at 100,000 g. The light membrane fraction
(plasma membrane) was collected in the 30% layer. Following SDS-in CPM/molecules and then the number of molecules per cell was
calculated. Loading efficiency at room temperature or 37C was PAGE on 10% acrylamide, proteins were electroblotted on nitrocel-
lulose filters, probed with rabbit polyclonal antibodies anti  PKCidentical but was reduced about 40% at 4C. Loading was linear
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(Santa Cruz Biotechnology), followed by goat polyclonal anti-rabbit selectin at physiologic flow rates: distinction from and prerequisite
for adhesion through integrins. Cell 65, 859–873.HRP conjugated (Sigma), and developed using ECL (Amersham).
Le Good, J.A., Ziegler, W.H., Parehk, D.B., Alessi, D.R., Cohen, P.,
Intravital Video Microscopy Analysis of Lymphocyte-High and Parker, P.J. (1998). Protein kinase C isotypes controlled by
Endothelial Venule Interaction in Peyer’s Patches phosphoinositide 3-kinase trough the protein kinase PDK1. Science
Lymphocytes (5  106/ml in DMEM without sodium bicarbonate 281, 2042–2045.
supplemented with 20 mM HEPES, 5% FCS (pH 7.1) were labeled Limatola, C., Barabino, B., Nista, A., and Santoni, A. (1997). Interleu-
with either CMFDA or CMTMR for 30 min at 37C. 30  106 labeled kin 1--induced protein kinase C- activation is mimicked by exoge-
cells were injected iv. In situ videomicroscopic analyses were carried nous phospholipase D. Biochem. J. 321, 497–501.
out in high endothelial venules (HEV) in the secondary lymphoid
Nagel, W., Zeiltmann, L., Schilcher, P., Gieger, C., Kolanus, J., and
organ Peyer’s patch as described (Constantin et al., 2000). Cell
Kolanus, W. (1998). Phosphoinositide 3-OH kinase activates the 2
behavior was analyzed over a period of 20–30 min starting at 2 min
integrin adhesion pathway and induces membrane recruitment of
after iv injection. Interactions of 1 s were considered significant
cytohesin-1. J. Biol. Chem. 273, 14853–14861.
and were scored. Cells were considered to be interacting whether
Prochiantz, A. (2000). Messenger proteins: homeoproteins, TAT andthey rolled, arrested, or both. Lymphocytes that remained firmly
others. Curr. Opin. Cell Biol. 12, 400–407.adherent on venular wall for 10 s were considered arrested.
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